<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00322543</url>
  </required_header>
  <id_info>
    <org_study_id>RAPID (Genesis) Registry CP-02</org_study_id>
    <nct_id>NCT00322543</nct_id>
  </id_info>
  <brief_title>Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID)</brief_title>
  <official_title>Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID) A Multi-Center Study of the Pimecrolimus-Eluting Cobalt Chromium Coronary Stent System (Corio™) in Patients With De Novo Lesions of the Native Coronary Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Conor Medsystems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Conor Medsystems</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-randomized, single arm, multi-center, clinical trial evaluating the Corio™&#xD;
      pimecrolimus-eluting stent with reduced anti-platelet therapy in patients with de novo&#xD;
      lesions of the native coronary arteries.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The registry is designed to evaluate 6-month in-stent late lumen loss in patients receiving&#xD;
      the Corio™ drug-eluting stent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic endpoint of in-stent late lumen loss at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE) defined as an adjudicated composite of clinically driven target vessel revascularization, new myocardial infarction (MI) or cardiac death at 30 days, 6 months, 12 months and 2 years;</measure>
    <time_frame>30 days, 6 months, 12 months and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device, Lesion and Procedural Success; Coronary angiography at 6 months; IVUS measurements in IVUS cohort at 6 months.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Drug eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Corio™ Pimecrolimus-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Corio™ Pimecrolimus-eluting stent</intervention_name>
    <arm_group_label>Drug eluting stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General Inclusion Criteria&#xD;
&#xD;
          1. Eligible for percutaneous coronary intervention (PCI).&#xD;
&#xD;
          2. Documented stable or unstable angina pectoris&#xD;
&#xD;
          3. Left ventricular ejection fraction (LVEF) ≥25%&#xD;
&#xD;
          4. Acceptable candidate for coronary artery bypass graft surgery (CABG).&#xD;
&#xD;
          5. Target Lesion &lt; 25 mm in length with RVD of 2.5 to 3.5 mm with visually estimated&#xD;
             stenosis of &gt;= 50 and &lt; 100 %.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Exclusion Criteria&#xD;
&#xD;
          1. Known sensitivity to pimecrolimus, the polymer (PLGA) or cobalt chromium.&#xD;
&#xD;
          2. Planned treatment with any other PCI device in the target vessel(s).&#xD;
&#xD;
          3. MI within 72 hours prior to the index procedure&#xD;
&#xD;
          4. The patient is in cardiogenic shock.&#xD;
&#xD;
          5. Cerebrovascular Accident (CVA) within the past 6 months.&#xD;
&#xD;
          6. Acute or chronic renal dysfunction&#xD;
&#xD;
          7. Contraindication to ASA or to clopidogrel.&#xD;
&#xD;
          8. Thrombocytopenia&#xD;
&#xD;
          9. Active gastrointestinal (GI) bleeding within the past 3 months.&#xD;
&#xD;
         10. Any prior true anaphylactiod reaction to contrast agents&#xD;
&#xD;
         11. Patient is currently taking chronic systemic steroid therapy or systemic&#xD;
             immunosuppressant therapy or topical pimecrolimus.&#xD;
&#xD;
         12. Female of childbearing potential.&#xD;
&#xD;
         13. Life expectancy of less than 24 months due to other medical conditions.&#xD;
&#xD;
         14. Co-morbid condition(s)&#xD;
&#xD;
         15. Currently participating in another investigational drug or device study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Abizaid, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute Dante Pazzanese of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute Dante Pazzanese of Cardiology</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04012-180</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>May 4, 2006</study_first_submitted>
  <study_first_submitted_qc>May 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2006</study_first_posted>
  <last_update_submitted>October 16, 2008</last_update_submitted>
  <last_update_submitted_qc>October 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Abizaid, MD</name_title>
    <organization>Institute Dante Pazzanese of Cardiology</organization>
  </responsible_party>
  <keyword>Percutaneous coronary intervention (PCI)</keyword>
  <keyword>Drug eluting stent (DES)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

